Summary

In the LEADLESS II trial, a leadless cardiac pacemaker was demonstrated to be safe and effective. At 6 months, the serious device-related adverse events occurred in 5.7% of patients, and the primary efficacy end point of acceptable pacing capture threshold and therapeutically acceptable sensing amplitude was achieved in 90% of patients.